Pharmaceuticals

Tangrensheng Xinxin Pharmaceutical Factory Obtains Registration Certificate for Loxoprofen Sodium Gel Patch

CMS Subsidiary Dermavon Applying for Separate Listing

TJ DaRenTang USD released FY2025 Q3 earnings on October 30 Pre-Market (SGT), actual revenue USD 143.18 M, actual EPS USD 0.0412

TJ DaRenTang USD released FY2025 9 Months Earnings on October 30 Pre-Market (SGT), actual revenue USD 510.18 M, actual EPS USD 0.387

TJ DaRenTang USD to Release FY2025 Q3 Earnings on October 31, Pre-Market SGT

IX Biopharma released FY2025 Q4 earnings on August 29 (SGT), actual revenue SGD 2.027 M, actual EPS SGD -0.0022

IX Biopharma released FY2025 Annual Earnings on August 29, 2025 (SGT) with actual revenue of SGD 7.767 M and EPS of SGD -0.0116

IX Biopharma released FY2025 9 Months Earnings on August 29 SGT, with actual revenue of SGD 5.74 M and EPS of SGD -0.0094

IX Biopharma released FY2025 Q3 earnings on August 29, 2025 (SGT) with actual revenue of SGD 2.027 M and EPS of SGD -0.0022

CMS released FY2025 Q1 earnings on August 18, 2025 (SGT) with actual revenue of SGD 369.58 M and EPS of SGD 0.0359

CMS released FY2025 Semi-Annual Earnings on August 18 During-Market SGT, actual revenue SGD 725.7 M (forecast SGD 712.11 M), actual EPS SGD 0.0705

CMS released FY2025 Q2 earnings on August 18 During-Market (SGT), actual revenue SGD 356.12 M, actual EPS SGD 0.0346

Pharmesis released FY2025 Semi-Annual earnings on August 14, 2025 (SGT) with actual revenue of SGD 4.933 M and EPS of SGD -0.0078

Pharmesis released FY2025 Q1 earnings on August 14, 2025 (SGT) with actual revenue of SGD 2.512 M and EPS of SGD -0.0039

Pharmesis released FY2025 Q2 earnings on August 14, Post-Market (SGT), actual revenue SGD 2.421 M, actual EPS SGD -0.0038

TJ DaRenTang USD released FY2025 Semi-Annual Earnings on August 14 During-Market (SGT), actual revenue USD 367.23 M, actual EPS USD 0.3463

TJ DaRenTang USD released FY2025 Q2 earnings on August 14 During-Market (SGT), actual revenue USD 166.65 M, actual EPS USD 0.2782

DatRenTang's 2025 H1 Report: Net Profit Surges 193.08%

Hyphens Pharma released FY2025 Semi-Annual Earnings on August 13, SGT with actual revenue of SGD 89.55 M and EPS of SGD 0.0053

Hyphens Pharma released FY2025 Q2 earnings on August 13, 2025 (SGT) with actual revenue of SGD 44.77 M and EPS of SGD 0.0026

< 1B

1B - 5B

5B - 10B

10B - 50B

50B - 100B

100B - 500B

500B - 1T

≥ 1T

Market Value

Total Assets

< 100M

100M - 500M

500M - 1B

≥ 100B

Revenue

0 - 50M

50M - 100M

≥ 10B

Profits

< 0%

0% - 5%

5% - 10%

10 - 15%

15% - 20%

20 - 25%

25% - 30%

>= 30%

ROE(TTM)

= 0%

0% - 1%

1% - 3%

3% - 5%

5% - 8%

8% - 10%

>= 10%

Dividend Yield

0% - 10%

10% - 15%

20% - 30%

30% - 40%

40% - 50%

>= 50%

Net Profit Margin

0 - 0.05

0.05 - 0.1

0.1 - 0.2

0.2 - 0.4

0.4 - 0.6

0.6 - 0.8

0.8 - 1

>= 1

Asset Turnover

< 1.5

1.5 - 2

2 - 3

3 - 5

5 - 10

10 - 15

15 - 20

>= 20

Equity Multiplier

< 10%

10% - 30%

30% - 50%

50% - 70%

70 - 80%

80% - 90%

90% - 95%

>= 95%

Debt Ratio

CapAllianz

Salt Investments

Pharmesis

STEng MBeCW260227

B&M Hldg

Ascent Bridge

Sin Heng Mach

Baidu MB eCW260505

GCCP

HSI 26800MBeCW260129

Hyphens Pharma International Limited has out-licensed its Cerapro® MED Skin Barrier Cream to Louis Widmer SA for commercialization in six European countries, including Switzerland and Belgium. The product, approved as a CE-marked medical device for treating atopic dermatitis, is set to launch in 2026. Hyphens Pharma will receive an upfront fee and royalties on sales. This partnership aims to leverage Louis Widmer's expertise in dermatology to enhance patient outcomes in Europe.

prnewswire

Hyphens Pharma

04:30 ET
			
			
				Hyphens Pharma out‑licences Cerapro® MED Skin Barrier Cream for six European countries

marketscreener

Haw Par

Haw Par Strikes Off Subsidiary

Nov 10 (Reuters) - IX Biopharma Ltd (IXBI.SI) :* TERM SHEET FOR PROPOSED JOINT VENTURE TO ESTABLISH MANUFACTURING AND COMMERCIALISATION BASE IN USA* NON-BINDING TERM SHEET WITH ORION SPECIALTY LABS Further company coverage: (IXBI.SI)

Reuters

IX Biopharma

IX Biopharma Enters Term Sheet For Proposed Joint Venture

IX Biopharma Raises Nearly SG$7 Million to Boost US Expansion; Shares Down 3%

IX Biopharma Raises Nearly SG$7 Million to Boost US Expansion; Shares Down 3%

IX Biopharma Receives Listing, Quotation Notice for Around 67 Million Shares

IX Biopharma Receives Listing, Quotation Notice for Around 67 Million Shares

SHENZHEN, CHINA, Oct. 30, 2025 ( GLOBE NEWSWIRE ) -- China Medical System Holdings Limited ( "CMS" ) is pleased to announce that its subsidiary, Dermavon Holdings Limited ( "Dermavon", an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the ...

GlobeNewswire

CMS; 8A8.SG )  NDA for AD Indication of Long-acting Anti-IL-4Rα Humanized Monoclonal Antibody Injection MG-K10 Accepted in China

iX Biopharma Ltd plans to raise at least $5 million through a share placement with OCBC, targeting institutional and accredited investors in Singapore. The funds will be allocated as follows: 40% for U.S. market expansion, 30% for equipment purchases, and 30% for working capital. The placement involves 50 million new shares priced at $0.100 each, representing a 9.67% discount to the VWAP. Completion is expected after receiving a listing notice from SGX Catalist, with a 90-day lock-up period for additional securities issuance.

Singapore Business Review

iX Biopharma to raise at least $5m via OCBC share placement

Ix Biopharma proposes placement to raise no less than S$5 million

Ix Biopharma proposes placement to raise no less than S$5 million

Pharmaceuticals(IN30219.SG)

04:30 ET Hyphens Pharma out‑licences Cerapro® MED Skin Barrier Cream for six European countries

Haw Par Strikes Off Subsidiary

IX Biopharma Enters Term Sheet For Proposed Joint Venture

IX Biopharma Raises Nearly SG$7 Million to Boost US Expansion; Shares Down 3%

IX Biopharma Receives Listing, Quotation Notice for Around 67 Million Shares